Get Involved

Einstein Junior study (Phase III)

Multi-centre randomised study to evaluate the efficacy and safety of an age and body weight-adjusted rivaroxaban regimen in children with acute venous thromboembolism.

Location: North East and North Cumbria

Contact phone number: Dr Tina Biss (0191) 2824743

Contact email: Tina.Biss@nuth.nhs.uk

Why is this study important?

Options for the treatment of thrombosis (blood clots) in children are limited. Anticoagulant (blood-thinning) therapy can either be with a tablet called warfarin which needs monitoring with regular blood tests, or a daily injection of heparin. Rivaroxaban is an anticoagulant that can be given as a tablet or syrup and does not need monitoring.

What is the aim of this study?

The aim is to see if rivaroxaban is as good at treating and preventing recurrence of blood clots in children as standard treatment (warfarin or heparin). The study will also see if rivaroxaban causes less or more bleeding than standard treatment.

What do people in this study have to do?

The study is for children aged 6 months to 17 years with a blood clot in a vein. At the start of their anticoagulant treatment they will be randomised to either standard treatment (warfarin or heparin) or rivaroxaban. There would be 4-5 visits to your hospital/clinic to check how your child is getting on. Treatment will continue for up to a year.

What are the risks and benefits for participants?

There is a risk of bleeding with all anticoagulant medicines. We do not yet know if rivaroxaban is as good as other anticoagulants in preventing further blood clots without causing unacceptable bleeding. The benefit is that the need for monitoring blood tests or daily injections can be avoided.

For further information about this study please contact

Dr Tina Biss (0191) 2824743

Recruitment to this study is due to end on:

This is not yet confirmed , in the meanwhile you can contact Dr Tina Biss for further information and we will update you on this site

A summary of the study findings should be available by:

Study findings will be published in the medical literature within 3-5 years.

Clinical Trials in Haematology

Select a trial from the list below to find out more about what it’s all about and how you can get involved in helping others.

Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism

The study is for patients with cancer who have been on a blood-thinner for a new clot for less than 3 days (and fit other criteria).

UK Adult Idiopathic Thrombocytopenic Purpura (ITP) Registry

This is a registry study that is aiming to recruit hundreds of individuals with ITP within the UK.

UK Childhood ITP Registry

The main aims of this project are to try and understand why some children with a low platelet count bleed, when there is a need for treatment and how having ITP impacts on the quality of life on the child and family.

The United Kingdom Thrombotic Thrombocytopenic Purpura Registry (TTP Registry)

The information from this study may help us to increase our understanding and improve future treatment for patients with TTP.

The molecular investigation of unexplained anaemias and related congenital anaemias

The study is for patients who have anaemia for which no cause has been found.

Einstein Junior study (Phase II)

The aim is see if rivaroxaban is as good at treating and preventing recurrence of blood clots in children as standard treatment (warfarin or heparin). The study will also see if rivaroxaban causes less or more bleeding than standard treatment.

Einstein Junior study (Phase III)

Options for the treatment of thrombosis (blood clots) in children are limited. Anticoagulant (blood-thinning) therapy can either be with a tablet called warfarin which needs monitoring with regular blood tests, or a daily injection of heparin. Rivaroxaban is an anticoagulant that can be given as a tablet or syrup and does not need monitoring.

ECHO: Expanding Communications on Haemophilia-A Outcomes

A prospective, international, longitudinal, observational disease registry of patient-reported outcomes (PROs), and clinical impact of Haemophilia A and its treatment in patients with moderate to severe Haemophilia A.

UK-PK

This study will observe feelings when discussing PK guided dosing with patients in the clinic & the process of discussing their own, personal PK profile after a brief educational session.


Latest news from PPI

View all